Form 4: Gilead CMO's Routine Stock Transactions Reported

Gilead Sciences' Chief Medical Officer, Dietmar Berger, reported the vesting and subsequent sale of shares from restricted stock units.

Summary

• Dietmar Berger, Chief Medical Officer of Gilead Sciences, Inc., reported transactions involving the company's common stock.
• On January 2, 2026, 16,326 restricted stock units (RSUs) vested, resulting in the acquisition of 16,326 shares of common stock.
• Concurrently, 6,944 shares were disposed of at a price of $121.6 per share, likely to cover tax obligations related to the RSU vesting.
• Following these transactions, Berger directly beneficially owns 9,382 shares of common stock and 41,179 restricted stock units.
• Each RSU represents the contingent right to receive one share of common stock and vests in approximately three equal installments on the first three anniversaries of the grant date.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to the vesting of restricted stock units and subsequent tax-related share dispositions, which are expected events in executive compensation. The vesting itself is a positive for the executive.

Positives

• The vesting of 16,326 restricted stock units (RSUs) for the Chief Medical Officer indicates the realization of long-term incentive compensation.
• The remaining 41,179 unvested RSUs represent a continued alignment of management's interests with shareholder value over the long term.

Negatives

• The disposition of 6,944 shares, while common for tax withholding, reduces the direct common stock holdings of the Chief Medical Officer.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor, as these are routine insider transactions and do not indicate a change in company fundamentals or strategy.

Next Steps

• Future vesting of the remaining 41,179 restricted stock units will occur in approximately three equal installments on the first three anniversaries of their grant date.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related share sales). It does not provide new fundamental information about Gilead Sciences' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, an investor would likely maintain their current position based solely on this filing.

Keywords

Gilead Sciences, GILD, Dietmar Berger, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Vesting, Executive Compensation, Common Stock